Wassim McHayleh, MD, FACP, MBA, on Elacestrant Plus Capivasertib in ER-Positive/HER2-Negative Advanced Breast Cancer: Update From ELEVATE
ASCO 2026
Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and preliminary efficacy for elacestrant and capivasertib for patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer who experienced disease progression on first-line endocrine therapy plus CDK4/6 inhibition (Abstract 1098).
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific T-cell engagers, antibody-drug conjugates, and radionuclide therapies.
The ASCO Post Staff
Jonathan W. Goldman, MD, of the University of California, Los Angeles, presents event-free survival data from the primary analysis of the phase III LIBRETTO-432 trial, which investigated the efficacy of the kinase inhibitor selpercatinib in patients with stage IB–IIIA RET fusion–positive non–small cell lung cancer (NSCLC) (Abstract LBA3).
The ASCO Post Staff
Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). At 5 years, median progression-free survival was not reached with lorlatinib in this population, representing the longest progression-free survival ever reported in advanced NSCLC (Abstract 8502).
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to bendamustine plus rituximab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); BRUIN CLL-314 is comparing pirtobrutinib to ibrutinib in the same patient population (Abstract 7044).
The ASCO Post Staff
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.
